Celexa May Be Hidden Trophy In Warner-Lambert Bidding War
Executive Summary
Forest's antidepressant Celexa could either become the centerpiece of a newly created neuropharmaceutical marketing giant or an outlicensing candidate, depending on whether American Home Products or Pfizer prevails in its bid to acquire Warner-Lambert.
You may also be interested in...
Forest Reclaiming Celexa Ahead Of Warner-Lambert Merger
Forest is exercising its option to regain full marketing rights to the antidepressant Celexa (citalopram) under the change-in-control provisions of its co-promotion agreement with Warner-Lambert.
Forest Reclaiming Celexa Ahead Of Warner-Lambert Merger
Forest is exercising its option to regain full marketing rights to the antidepressant Celexa (citalopram) under the change-in-control provisions of its co-promotion agreement with Warner-Lambert.
Pfizer In Two-Front Battle To Defend Product-Line Amid Merger Talks
Speculation about potential mergers involving Monsanto may raise the stakes for Pfizer in its bid to acquire Warner-Lambert.